Search results
Showing 706 to 720 of 2106 results for technology appraisal
Navepegritide for treating achondroplasia in people 2 to 15 years [ID6538]
Awaiting development Reference number: GID-TA11699 Expected publication date: TBC
Etelcalcetide for treating secondary hyperparathyroidism (TA448)
Evidence-based recommendations on etelcalcetide (Parsabiv) for treating secondary hyperparathyroidism in adults with chronic kidney disease on haemodialysis.
Eneboparatide for treating chronic hypoparathyroidism [ID6532]
Awaiting development Reference number: GID-TA11688 Expected publication date: TBC
Awaiting development Reference number: GID-TA11590 Expected publication date: TBC
Amantadine, oseltamivir and zanamivir for the treatment of influenza (TA168)
Evidence-based recommendations on amantadine (Lysovir), oseltamivir (Tamiflu) and zanamivir (Relenza) for treating influenza in children and adults.
Cardiovascular risk assessment and lipid modification (QS100)
This quality standard covers identifying and assessing cardiovascular risk in adults without cardiovascular disease, and treatment to prevent primary and secondary cardiovascular disease. It describes high-quality care in priority areas for improvement.
View quality statements for QS100Show all sections
Sections for QS100
- Quality statements
- Quality statement 1: Identifying adults who are likely to be at high risk
- Quality statement 2: Diet and lifestyle advice for primary prevention
- Quality statement 3: Lipid-lowering treatment for primary prevention
- Quality statement 4: Assessing response to lipid-lowering treatment
- Quality statement 5: Secondary prevention of cardiovascular disease
- Update information
- About this quality standard
Evidence-based recommendations on lutetium (177Lu) oxodotreotide (Lutathera) for treating unresectable or metastatic neuroendocrine tumours in adults.
Summary of the evidence on cangrelor for coronary revascularisation to inform local NHS planning and decision-making
In development Reference number: GID-TA11221 Expected publication date: TBC
Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and over (TA1077)
Evidence-based recommendations on nemolizumab (Nemluvio) for treating moderate to severe atopic dermatitis in people 12 years and over.
Evidence-based recommendations on atezolizumab (Tecentriq) for previously treated locally advanced or metastatic urothelial carcinoma in adults.
Awaiting development Reference number: GID-TA11336 Expected publication date: TBC
Awaiting development Reference number: GID-TA11162 Expected publication date: 28 July 2027
Awaiting development Reference number: GID-TA11626 Expected publication date: TBC
Membership details, terms of reference and future meeting dates for our quality standards advisory committee.